Lifeward (NASDAQ:LFWD) Announces Earnings Results, Misses Estimates By $0.07 EPS

Lifeward (NASDAQ:LFWD) released its earnings results on Friday. The company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($1.39) by ($0.07), FiscalAI reports. The company had revenue of $6.62 million for the quarter, compared to analysts’ expectations of $6.53 million. Lifeward had a negative net margin of 123.66% and a negative return on equity of 243.14%.

Lifeward Price Performance

Shares of LFWD stock traded down $0.44 on Friday, hitting $7.45. 16,937 shares of the stock traded hands, compared to its average volume of 6,192. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.40 and a quick ratio of 1.82. Lifeward has a 52 week low of $4.14 and a 52 week high of $10.56. The firm has a 50 day simple moving average of $7.43 and a two-hundred day simple moving average of $6.99. The firm has a market cap of $21.08 million, a price-to-earnings ratio of -0.38 and a beta of 0.38.

Institutional Investors Weigh In On Lifeward

A number of institutional investors have recently bought and sold shares of LFWD. Citadel Advisors LLC raised its holdings in Lifeward by 1,271.8% during the third quarter. Citadel Advisors LLC now owns 214,006 shares of the company’s stock valued at $152,000 after acquiring an additional 198,406 shares during the period. Virtu Financial LLC boosted its stake in shares of Lifeward by 158.0% in the fourth quarter. Virtu Financial LLC now owns 60,474 shares of the company’s stock worth $35,000 after acquiring an additional 37,037 shares during the period. Jane Street Group LLC boosted its stake in shares of Lifeward by 77.3% in the fourth quarter. Jane Street Group LLC now owns 68,631 shares of the company’s stock worth $40,000 after acquiring an additional 29,927 shares during the period. Finally, HRT Financial LP boosted its stake in shares of Lifeward by 149.7% in the fourth quarter. HRT Financial LP now owns 49,081 shares of the company’s stock worth $28,000 after acquiring an additional 29,423 shares during the period. Hedge funds and other institutional investors own 26.76% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Weiss Ratings raised Lifeward from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 3rd. Zacks Research upgraded Lifeward from a “strong sell” rating to a “hold” rating in a research note on Monday, July 27th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $10.00.

About Lifeward

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.